Ascendis Pharma A/S $ASND Shares Purchased by Sigma Planning Corp

Sigma Planning Corp raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 170.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,104 shares of the biotechnology company’s stock after acquiring an additional 2,589 shares during the quarter. Sigma Planning Corp’s holdings in Ascendis Pharma A/S were worth $708,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in ASND. Gilbert & Cook Inc. grew its stake in shares of Ascendis Pharma A/S by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 6,750 shares of the biotechnology company’s stock worth $1,165,000 after purchasing an additional 131 shares during the period. Chicago Partners Investment Group LLC lifted its stake in shares of Ascendis Pharma A/S by 4.5% in the second quarter. Chicago Partners Investment Group LLC now owns 3,732 shares of the biotechnology company’s stock valued at $635,000 after purchasing an additional 161 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Ascendis Pharma A/S by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company’s stock worth $1,337,000 after buying an additional 195 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new position in Ascendis Pharma A/S during the second quarter worth about $39,000. Finally, Hantz Financial Services Inc. grew its position in Ascendis Pharma A/S by 291.1% during the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock worth $61,000 after buying an additional 262 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $295.00 price target (up from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Stifel Nicolaus lifted their price objective on Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research report on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.80.

Ascendis Pharma A/S Stock Down 0.8%

Shares of NASDAQ:ASND opened at $197.74 on Friday. The company has a market cap of $12.20 billion, a P/E ratio of -38.32 and a beta of 0.44. The business has a fifty day simple moving average of $201.67 and a 200-day simple moving average of $183.19. Ascendis Pharma A/S has a 52 week low of $118.03 and a 52 week high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to analyst estimates of $163.17 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.